Amgen Inc. (AMGN) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: Setup is constructive but not stretched — consensus is a manageable bar, the six growth drivers are accelerating, and the biggest swing factor is whether denosumab erosion is tracking in-line or worse than the "accelerated" trajectory management guided.

Heading into Q2 2026, Amgen's setup is broadly positive: the six key growth drivers (Repatha, EVENITY, TEZSPIRE, rare disease, innovative oncology, and biosimilars) collectively grew 24% YoY in Q1 and represented ~70% of product sales, and consensus expects that momentum to continue with Q2 revenue of ~$9.43B (+2.7% vs. Q1 actuals) and non-GAAP EPS of ~$5.58. Management raised full-year guidance at Q1 to $37.1–38.5B revenue and $21.70–23.10 non-GAAP EPS, and explicitly guided Q2 operating margin "in line" with Q1's 45.3%, giving the Street a clear anchor. Estimate revisions have been remarkably stable since the Q1 print — Q2 revenue consensus has drifted only ~+$0.1B and FY EPS has edged slightly lower (~$22.36 vs. $22.42 post-Q1), suggesting the market is neither chasing upside nor pricing in a miss. The stock has rallied ~11% since the April 30 earnings date (vs. XLV +11% and SPY +4%), meaning AMGN has kept pace with the sector but not materially outperformed, leaving the multiple at ~16.7x NTM P/E — in-line with large-cap biotech peers and not pricing in a significant beat. The key wildcard is the July 31 cybersecurity 8-K (data exfiltrated from cloud environments, determined material but "not reasonably likely" to impact financials) — management's tone and any incremental disclosure on this incident will be closely watched, as will the trajectory of Prolia/XGEVA erosion, which management flagged as "accelerating" through the remainder of 2026.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a manageable bar — Q2 revenue of ~$9.43B implies modest sequential growth and the Street is not pricing in a heroic beat. UPLIZNA and Repatha are the biggest swing factors: both have been consistently beating consensus, and any upside surprise there would likely drive the stock. Denosumab (Prolia + XGEVA) erosion is the key downside risk.

Table 1 — Current Quarter Snapshot (Q2 2026)

Source: Visible Alpha Consensus and Actuals Data

Table 2 — Beat/Miss History: Last 8 Quarters

Top KPI #1: Total Revenue | Top KPI #2: Non-GAAP EPS (Diluted)

Pattern: Amgen has beaten consensus on both revenue and non-GAAP EPS in 7 of the last 8 quarters, with EPS beats consistently larger than revenue beats (averaging ~10% on EPS vs. ~3% on revenue). The one revenue in-line quarter (Q3 2024) still produced a meaningful EPS beat, underscoring strong cost discipline. The bar for Q2 2026 is set modestly, consistent with the historical pattern.

Source: Visible Alpha Consensus and Actuals Data

3. Guidance & Commentary Evolution

Key Takeaway: Guidance was raised at Q1 2026 earnings (April 30) and has not been formally revised since. Management tone remains confident — the "springboard year" framing is intact — but the July 31 cybersecurity 8-K introduces a new overhang that will require management to address on the call.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been remarkably stable since the Q1 print — Q2 revenue consensus has drifted only ~+$0.1B and FY EPS has edged slightly lower (~$22.36 vs. $22.42 post-Q1). Estimates are tracking guidance, not diverging, which means there is no embedded cushion from downward revisions and no risk from upward-revised expectations. The gap between consensus and guidance midpoints is narrow, suggesting the Street is comfortable with management's framework.

Source: Visible Alpha Consensus and Actuals Data. Note: The post-Q1 baseline date of May 8, 2026 (5 trading days after the April 30 earnings release) is used as the clean post-print consensus starting point. Estimates have been essentially flat since the Q1 print, confirming the Street is comfortable with management's guidance framework and not making incremental adjustments. The slight FY EPS drift lower (−0.3%) likely reflects minor mix-shift assumptions rather than any fundamental concern.

5. Stock Performance

Key Takeaway: AMGN's +11% gain since Q1 earnings (April 30 – August 3) has been driven by multiple expansion rather than estimate revisions — NTM P/E expanded from ~15.7x to ~16.7x while EPS estimates were essentially flat. The stock has kept pace with XLV (+11%) but significantly outperformed the S&P 500 (+5%), suggesting sector rotation into defensive healthcare has been the primary driver rather than AMGN-specific alpha.

Performance Summary (April 30 – August 3, 2026):

Source: Stock Price Data (Yahoo Finance). Note: Aug 3 close used as the most recent available price. AMGN slightly underperformed XLV over the period, consistent with the stock being a quality compounder rather than a high-beta growth name. The notable spike to $393 on July 28 (ABBV Q2 earnings day / sector rally) partially reversed, suggesting the move was sector-driven. The July 31 cybersecurity 8-K filing did not appear to materially impact the stock, with shares closing at $385 on July 31 and $378 on August 4.

Valuation Context: NTM P/E expanded from ~15.7x (April 30) to ~16.7x (August 3), accounting for the majority of the stock's gain given flat EPS estimates. At 16.7x NTM P/E, AMGN trades in-line with large-cap biotech peers and at a modest premium to its own 12-month trailing average of ~15.4x. The stock is not pricing in a significant beat, but it is also not pricing in a miss — a clean Q2 print with maintained guidance should be well-received.

Key Events Since Last Earnings (marked on chart):

• May 4–5, 2026: Amgen announced ~$300M additional Puerto Rico investment (total ~$1B commitment); insider sale by SVP & CCO Nancy Grygiel (1,237 shares, $1,237 × ~$329 = ~$407K, open market, non-10b5-1).
• June 4, 2026: Amgen presented at Goldman Sachs 47th Annual Global Healthcare Conference.
• July 28, 2026: AMGN announced webcast of Q2 2026 financial results (August 4 after close).
• July 31, 2026: Amgen filed 8-K disclosing material cybersecurity incident — data exfiltrated from cloud environments; no impact to products, manufacturing, or financial reporting systems identified as of filing date.

6. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the July 31 cybersecurity 8-K — while management stated it is "not reasonably likely" to impact financials, the disclosure of exfiltrated proprietary data and patient PHI creates reputational and regulatory risk that will dominate Q&A. Pipeline-wise, the TEPEZZA subcutaneous Phase III success and IMDELLTRA European approval are the most commercially significant positive developments.

• July 31, 2026 — Cybersecurity Incident (8-K): Amgen disclosed unauthorized access to cloud-hosted data environments, with exfiltration of proprietary data, patient PHI, and other information. Determined material on July 29. No impact to products, manufacturing, or financial reporting systems identified. Investigation ongoing. Implication: Management must address scope, remediation costs, and regulatory notification obligations on the Q2 call; any incremental disclosure could be a negative catalyst.
• April 30, 2026 — TEPEZZA Subcutaneous Phase III Positive Topline: Phase III trial of TEPEZZA via on-body injector (OBI) demonstrated comparable efficacy to IV TEPEZZA (77% proptosis response rate at week 24 vs. 19.6% placebo). Implication: Supports subcutaneous administration pathway, expands sites of care, and could meaningfully grow the addressable TED market by reducing infusion center dependency.
• June 2026 — IMDELLTRA European Commission Approval: EC approved IMDELLTRA (tarlatamab) for extensive-stage small cell lung cancer in Europe, expanding the global commercial opportunity. Implication: Incremental revenue contributor in 2H 2026; physician community described as "highly excited" about frontline and maintenance settings following ASCO 2026 data.
• May 4–5, 2026 — Puerto Rico Investment Expansion: Amgen announced an additional ~$300M investment in Puerto Rico (total ~$1B commitment), reinforcing the strategic importance of the Juncos biologics facility. Implication: Signals long-term manufacturing commitment and may be relevant to the ongoing IRS tax dispute regarding Puerto Rico profit allocation.
• April 30, 2026 — MariTide Phase III Expansion (Switch + Maintenance Studies): Amgen initiated MARITIME-SWITCH (evaluating transition from weekly GLP-1s to MariTide on every 8- or 12-week schedule) and two long-term maintenance extension studies. Implication: Signals deliberate positioning as a later-entry but more convenient alternative; total Phase III program now tracking toward ~12 studies.
• April 30, 2026 — AMG 193 (PRMT5 Inhibitor) Discontinued: Following comprehensive review, Amgen discontinued development of AMG 193 across multiple oncology indications. Implication: Pipeline pruning consistent with AI-driven R&D prioritization; frees resources for higher-conviction assets.
• April 27–30, 2026 — TAVNEOS FDA Proposed Withdrawal: FDA's CDER proposed to withdraw TAVNEOS approval, citing data manipulation concerns in the original ChemoCentryx ADVOCATE trial and new post-marketing safety signals (drug-induced liver injury, vanishing bile duct syndrome). TAVNEOS remains on market pending resolution. Implication: Modest revenue impact (~$119M in Q1 2026), but reputational and regulatory overhang; Amgen is contesting the action.
• April 30, 2026 — Subcutaneous Blinatumomab Enrollment Paused: Enrollment paused in potentially registration-enabling Phase 2 study due to inflammatory reactions; management expected to reopen "shortly" after FDA dialogue. Implication: Minor delay to a potential label expansion; watch for update on enrollment status on Q2 call.
• April 30, 2026 — IRS Draft NOPA (2016–2018 Tax Years): IRS issued draft Notice of Proposed Adjustment asserting significant adjustments related to Puerto Rico profit allocation. Amgen disputes the methodology; management provided detailed breakdown of offsets suggesting actual cash exposure is materially lower than headline figures. Implication: Ongoing contingent liability; Tax Court decision on 2010–2015 years expected no earlier than 2H 2026.
• June 4, 2026 — Goldman Sachs Global Healthcare Conference: Amgen presented; no material guidance changes disclosed. Implication: Consistent with management's practice of not providing incremental guidance at conferences.

7. Insider Transaction Activity

Key Takeaway: Insider activity since Q1 earnings is minimal — a single open-market sale by the SVP & Chief Commercial Officer in early May. No clustered buying, no unusual sale size, and no 10b5-1 plan initiations disclosed. The absence of insider buying is not a negative signal given the stock's strong run, but the lack of any open-market purchases is notable.

Source: SEC Form 4 Filings (Insider Transaction Data). Note: Only open-market transactions (Form 4 codes P/S) are included. The sale by the CCO is modest in size relative to her retained position and does not represent a meaningful bearish signal. No Form 144 filings (intended sales) were identified in the period. No open-market purchases were disclosed by any insider since the Q1 earnings date.

8. Peer Commentary & Read-Through

Key Takeaway: Peer Q2 2026 earnings calls (reported July 15–31) provide several forward-looking read-throughs for AMGN's Q2 and 2H 2026 outlook. The most actionable signals are: (1) GSK's J-code activation for a severe asthma biologic on July 1 confirms improving reimbursement dynamics for TEZSPIRE; (2) Novartis's commentary on the large unmet need in lipid lowering and the segmentation of the PCSK9 market is constructive for Repatha; (3) AbbVie's confirmation of stable payer negotiation dynamics (low single-digit concessions) is a neutral-to-positive read for AMGN's immunology portfolio; and (4) JNJ's observation of no broad-based slowdown in healthcare demand is a positive macro read-through. All commentary below is forward-looking only — retrospective peer Q2 results commentary has been excluded per the user's instruction.

8.1 Immunology / Inflammation — Severe Asthma (TEZSPIRE Read-Through)

Source: GSK Q2 2026 Earnings Call (July 28, 2026)

GSK Commentary (Forward-Looking — 3Q/2H 2026): GSK's SVP of Global Product Strategy noted that the J-code for Extensor (its twice-yearly IL-5 for severe asthma) "went live on July 1st, reducing the logistical burden on prescribers and providing certainty on reimbursement," and that "more than 50% of insured patients are now being covered."

Relevance for AMGN: AMGN markets TEZSPIRE (tezepelumab) for severe asthma. The J-code activation for a competing severe asthma biologic on July 1 confirms that the reimbursement environment for biologics in this space is improving and that payers are actively covering new entrants. This is a positive read-through for TEZSPIRE's access trajectory in 2H 2026, as the same favorable reimbursement dynamics should benefit TEZSPIRE, which has a differentiated TSLP mechanism and broader patient eligibility than IL-5 inhibitors.

Limits: Extensor is an IL-5 inhibitor targeting a specific inflammatory pathway; TEZSPIRE is a TSLP inhibitor with a broader mechanism. The J-code dynamics are specific to Extensor's administration setting and may not translate directly to TEZSPIRE's reimbursement pathway. Additionally, GSK's commentary also noted "softer inhaled respiratory market demand" in Q2, which could imply some near-term headwinds for the broader respiratory market, though this was expected to improve in 2H.

8.2 Cardiovascular / Lipid Lowering — PCSK9 Market Dynamics (Repatha Read-Through)

Source: Novartis Q2 2026 Earnings Call (July 21, 2026)

Novartis Commentary (Forward-Looking — 3Q/2H 2026): Novartis management highlighted that there is a "significant segment of the market" for advanced lipid-lowering therapies, with "70 million patients overall" in the US not at goal. They emphasized "ongoing demand for patients who want infrequently administered therapies" and noted that Leqvio (inclisiran, an siRNA) is "not participating in the gross-to-net battle that will ensue between the monoclonal antibodies and the orals," suggesting a segmented competitive landscape where different administration routes occupy distinct market niches. Separately, Novartis flagged an upcoming readout for Pelacarsen (an Lp(a)-lowering agent) in the "coming months," noting that "in the mid-teens is clinically meaningful" for a cardiovascular outcomes benefit.

Relevance for AMGN: The commentary on the 70M patient unmet need and the segmentation of the lipid-lowering market is constructive for Repatha's growth runway. Novartis's framing of Leqvio as occupying a distinct niche (physician-administered, Part B buy-and-bill) from PCSK9 monoclonal antibodies (Part D, self-administered) suggests that Repatha is not directly threatened by Leqvio's growth. The Pelacarsen readout is relevant because AMGN has its own Lp(a)-lowering asset (Olpasiran, in Phase III OCEAN(a) outcomes study) — a positive Pelacarsen result would validate the Lp(a) target and could be a positive read-through for Olpasiran's commercial potential.

Limits: Leqvio is an siRNA with a different mechanism and administration route than Repatha; the competitive dynamics are distinct. Pelacarsen and Olpasiran both target Lp(a) but are different molecules with different trial designs and patient populations. A Pelacarsen success does not guarantee Olpasiran success, and vice versa.

8.3 Immunology / Payer Dynamics (Otezla / Enbrel Read-Through)

Source: AbbVie Q2 2026 Earnings Call (July 31, 2026)

AbbVie Commentary (Forward-Looking — 3Q/2H 2026): AbbVie management described ongoing 2027 payer negotiations as "tough but relatively consistent with prior years," expecting "low single-digit concessions around rebates and price concessions as the standard" in immunology, which they characterized as a "volume-driven business." They also noted that Skyrizi's momentum in psoriasis has not seen a "material change" since new competitor launches, with new competitor share "sourced from the two other orals in the marketplace" rather than from Skyrizi, and that the psoriasis market is "expanding" rather than being cannibalized.

Relevance for AMGN: The "low single-digit concessions" framing is a neutral-to-positive read for AMGN's immunology portfolio (Otezla, Enbrel, Amjevita), suggesting that payer pressure in immunology is not escalating beyond historical norms heading into 2027 contracting. The commentary that new oral entrants in psoriasis are taking share from other orals (not from biologics) is a positive read-through for Otezla's competitive positioning, as it suggests the oral psoriasis market is expanding rather than being cannibalized by new entrants.

Limits: AbbVie's payer negotiation dynamics are specific to its portfolio (Skyrizi, Rinvoq), which has different market positioning and leverage than AMGN's immunology products. Enbrel faces IRA pricing pressure (Medicare Part D price setting effective January 1, 2026) that is distinct from the standard rebate negotiation dynamics AbbVie described. Otezla's competitive dynamics in psoriasis may differ from Skyrizi's given different mechanisms and patient populations.

8.4 Oncology — Multiple Myeloma & Bispecific Antibodies (Kyprolis / BLINCYTO Read-Through)

Source: Bristol Myers Squibb Q2 2026 Earnings Call (July 30, 2026)

BMY Commentary (Forward-Looking — 3Q/2H 2026): BMY is awaiting an August 17 PDUFA date for Iberdomide (a "cell mod" oral therapy for multiple myeloma), which has the potential to be the "first commercialized cell model" in MM. Management noted that PFS data will be available "within just a few months after approval," which is expected to "accelerate uptake." BMY also noted that "typical summer demand patterns" are expected to "moderate growth in the third quarter" for cell therapy products like Breyanzi.

Relevance for AMGN: The anticipated launch of Iberdomide in MM is relevant for AMGN's Kyprolis (carfilzomib), which competes in the relapsed/refractory MM space. A new oral cell mod class could shift treatment paradigms and potentially increase competitive pressure on existing MM therapies. The "summer demand moderation" commentary for cell therapies is a minor negative read-through for BLINCYTO (blinatumomab), which is administered in a similar institutional setting, though BLINCYTO's primary indication (B-ALL) is distinct from MM.

Limits: Iberdomide is an oral therapy targeting a different mechanism than Kyprolis (proteasome inhibitor). The competitive impact on Kyprolis depends on Iberdomide's positioning in the treatment sequence and whether it is used in combination with or instead of existing therapies. The summer demand moderation is a seasonal pattern specific to cell therapies and may not apply to BLINCYTO's patient population.

8.5 Biosimilars — Originator Erosion Dynamics (Biosimilar Portfolio Read-Through)

Source: Johnson & Johnson Q2 2026 Earnings Call (July 15, 2026)

JNJ Commentary (Forward-Looking — 3Q/2H 2026): JNJ noted that Stelara "declined 55.7%, driven by share loss due to biosimilar competition" in Q2, and this impact is expected to continue into 2H 2026. JNJ also stated they are "not seeing evidence of a broad-based slowdown in demand" for healthcare products and that their diversified business is "less dependent on discretionary elective procedures."

Relevance for AMGN: JNJ's Stelara biosimilar erosion experience is a positive read-through for AMGN's biosimilar portfolio — AMGN markets ABP 654 (biosimilar Stelara/ustekinumab), and the rapid and substantial erosion of Stelara's market share confirms that biosimilar penetration in this category is proceeding aggressively, which should benefit AMGN's biosimilar revenue. JNJ's "no broad-based slowdown in demand" commentary is a positive macro read-through for AMGN's overall commercial portfolio.

Limits: JNJ's Stelara erosion is backward-looking in nature (Q2 results), but the forward-looking implication is that biosimilar penetration will continue in 2H 2026. AMGN's specific share of the Stelara biosimilar market depends on its competitive positioning against other biosimilar entrants (Sandoz, Teva, etc.). The "no slowdown in demand" commentary is specific to JNJ's diversified portfolio and may not fully translate to AMGN's specific therapeutic areas.

8.6 Rare Disease / Immunology — Sjögren’s Disease Market Creation (Dazodalibep Read-Through)

Source: Novartis Q2 2026 Earnings Call (July 21, 2026)

Novartis Commentary (Forward-Looking — 3Q/2H 2026): Novartis management stated they are "on track for a Q3 approval" for Zanolimumab in Sjögren's disease, with a "US launch in Sjögren's disease in the second half." They anticipate "relatively broad access" given "no approved therapy in Sjögren's" and expect physicians to "err on the side of trialing the drug." They also noted that the drug has a "clean safety profile."

Relevance for AMGN: AMGN has dazodalibep (a first-in-class CD40 ligand targeting fusion protein) in Phase III for Sjögren's syndrome, with both systemic and symptomatic studies fully enrolled and results expected in 2H 2026. Novartis's anticipated launch of Zanolimumab in Sjögren's is a double-edged read-through: it validates the commercial opportunity in a disease with no approved therapies and confirms that payers are likely to provide broad access for first-in-class agents in this indication, but it also means AMGN's dazodalibep would enter a market where a competitor has already established a presence if it receives approval.

Limits: Zanolimumab and dazodalibep have different mechanisms of action (Zanolimumab targets CD19 B-cells; dazodalibep targets CD40 ligand). The competitive dynamics will depend on their respective efficacy and safety profiles in the Phase III readouts. AMGN's dazodalibep data are not yet available, and the Phase III readout timing in 2H 2026 creates binary event risk.

8.7 AstraZeneca — Inhaled TSLP Collaboration (Direct AMGN Pipeline Read-Through)

Source: AstraZeneca Q2 2026 Earnings Call (July 27, 2026)

AstraZeneca Commentary (Forward-Looking — 3Q/2H 2026): AstraZeneca management noted that following Phase 2 study readouts for their inhaled TSLP program (AZD 8630, co-developed with Amgen), they are "discussing plans for Phase 3 with their partner, Amgen." This is a direct reference to a shared pipeline asset.

Relevance for AMGN: This is a direct pipeline read-through — AZN's commentary confirms that the inhaled TSLP program (AZD 8630) has progressed through Phase 2 and that Phase 3 planning discussions are underway with AMGN. This is a potential future commercial product in respiratory/immunology that is not yet in AMGN's consensus estimates. A Phase 3 initiation announcement on the Q2 call would be a positive catalyst.

Limits: Phase 3 planning discussions do not guarantee Phase 3 initiation or ultimate approval. The inhaled TSLP program is in early stages relative to AMGN's marketed TEZSPIRE (IV tezepelumab), and the two products would target different patient populations (inhaled vs. IV administration). The commercial opportunity and timeline are highly uncertain.

8.8 Healthcare Utilization & Pricing — Macro Read-Through

Source: Johnson & Johnson Q2 2026 Earnings Call (July 15, 2026) | AstraZeneca Q2 2026 Earnings Call (July 27, 2026)

Commentary (Forward-Looking — 3Q/2H 2026): JNJ stated they are "not seeing evidence of a broad-based slowdown in demand" and that ACA subsidy removals are "not expected to translate into a material impact on demand for medtech and procedures." JNJ also noted that operational sales growth is expected to "improve in the second half of the year." AstraZeneca highlighted that pricing negotiations for innovative therapies are reflecting a "new reality" where funding for innovation needs to rise in line with GDP per capita, and that discussions are "anticipated to take more time than in the past."

Relevance for AMGN: JNJ's "no broad-based slowdown" commentary is a positive macro read-through for AMGN's commercial portfolio, suggesting that underlying healthcare demand remains robust heading into 2H 2026. AZN's commentary on longer pricing negotiation timelines is a mild negative read-through for AMGN's international pricing dynamics, particularly for newer products like IMDELLTRA and UPLIZNA that are in the early stages of global market access negotiations.

Limits: JNJ's demand commentary is primarily driven by its MedTech portfolio (orthopedics, surgery, vision), which has different demand drivers than AMGN's pharmaceutical products. AZN's pricing commentary is specific to its own launch portfolio and negotiation dynamics; AMGN's specific pricing outcomes will depend on its own product value propositions and market access strategies.

Peer Read-Through Summary Table

Note on Methodology: All peer commentary included above is strictly forward-looking — referring to 3Q 2026, 2H 2026, or full-year 2026 conditions and outlook. Retrospective commentary by peers about their own Q2 2026 results has been excluded. Peers included: GSK (Jul 28), Novartis (Jul 21), AbbVie (Jul 31), Bristol Myers Squibb (Jul 30), Johnson & Johnson (Jul 15), AstraZeneca (Jul 27). Biogen (Jul 29) was reviewed but its forward-looking commentary (SLE/CLL readouts, Leqembi subcutaneous launch) was assessed as having limited direct commercial read-through for AMGN's current reporting quarter and was excluded.